Skip to main content
Premium Trial:

Request an Annual Quote

Metabolon, Merck KGaA Form Metabolomics Alliance

NEW YORK — Metabolon has signed a multiyear drug development alliance with Germany's Merck KGaA, the companies said on Monday.

Under the terms of the deal, Metabolon will apply its Precision Metabolomics liquid chromatography-mass spectrometry global metabolomics platform — which identifies pharmacodynamic, efficacy, and response biomarkers and tracks changes in biological pathways — to undisclosed early-stage drug development programs across therapeutic areas at Merck.

Additional terms were not disclosed.

In early 2018, Morrisville, North Carolina-based Metabolon was selected to perform large-scale metabolomic profiling on samples from US veterans as part of the US Department of Veterans Affairs' Million Veteran Program.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.